Issue link: https://beckershealthcare.uberflip.com/i/1198635
19 DEVICES & IMPLANTS Orthopedic market share projections: Top 5 companies in 2024 By Laura Dyrda S tatista released a report projecting which companies will have the biggest orthopedic medical technology market share in 2024. The top five companies include: 1. Johnson & Johnson: 21.8 percent 2. Zimmer Biomet: 18.8 percent 3. Stryker: 18 percent 4. Medtronic: 8 percent 5. Arthrex: 6 percent Statista also calculated market share for 2017 and found that three of the top five companies — Johnson & Johnson, Zimmer Biomet and Medtronic — are expected to lose market share during the seven-year period examined. Stryker is expected to gain 1.7 percent market share. Stryker acquired K2M last year, improving its spine business line. Medtronic has also made key acquisitions since the report was last up- dated in October 2018, including the purchase of Titan Spine for an undisclosed sum in June. Titan Spine is a surface technology company focused on minimally invasive spine devices. n Bioventus, UnitedHealthcare agree to commercial contract for HA-based products By Alan Condon O rthobiologic company Bioventus signed a nationwide contract with UnitedHealthcare employer and individual commercial plans this week. Three things to know: 1. Bioventus' Durolane and Gelsyn-3 treatments for knee osteoarthri- tis pain will be made available to UnitedHealthcare commercial plan members starting Oct. 1. 2. Durolane is a single-injection and Gelsyn-3 is a three-injection hyal- uronic acid-based joint fluid treatment. 3. Bioventus plans to expand Durolane into Australia and New Zealand and is launching Durolane SJ — another HA-based product — in both countries later this year. n What Stryker's spine division stands to gain from 5 acquisitions By Angie Stewart S tryker's decision to acquire Mobius Imaging for $370 million is one of several transactions the company has pursued to bolster its spine division, according to Zacks Equity Research. Stryker's spine division offers a broad portfolio in- cluding interbody devices, radiofrequency ablation products, spine navigation devices and cervical fix- ation devices. Five acquisitions Stryker stands to gain from: Mobius Imaging. Stryker will enter the intraoper- ative imaging space by acquiring Mobius Imaging for $370 million upfront with up to $130 million of contingent payments. Mobius Imaging's Airo TruCT scanner is expected to be an asset to Stryker's spine division. K2M. Stryker acquired K2M for $1.4 billion in late 2018. At the time, analysts said the acquisition would help Stryker scale and innovate in the com- plex spine segment. Zacks Equity Research believes the transaction will be accretive for Stryker's spine division. Arrinex. Stryker expanded the ENT portfolio with- in its spine segment with its buyout of Arrinex ear- lier this year. Arrinex's ClariFix device gave Stryker the opportunity to address a "large, underpenetrat- ed segment of the ENT market," the company said. HyperBranch Medical Technology. Stryker paid $220 million for HyperBranch Medical and its Ad- herus AutoSpray, a dural sealant. "e addition of Adherus to our cranial closure portfolio strengthens our position of excellence in the dural repair space and aligns with Stryker's mission of making health- care better," said Spencer S. Stiles, Stryker's group president of neurotechnology, instruments and spine, when the transaction closed in October 2018. Invuity. Also in October 2018, Stryker acquired In- vuity for a total equity value of about $190 million, a move that was expected to complement Stryker's instruments business. Invuity's single-use lighted in- strumentation and enhanced energy products were designed to enhance visualization for orthopedic and spine surgery. n